Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

VEGFR2 activation mediates the pro-angiogenic activity of BMP4.

Rezzola S, Di Somma M, Corsini M, Leali D, Ravelli C, Polli VAB, Grillo E, Presta M, Mitola S.

Angiogenesis. 2019 Jul 30. doi: 10.1007/s10456-019-09676-y. [Epub ahead of print]

PMID:
31363885
2.

Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells.

Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W, Presta M.

Mol Cancer Ther. 2013 Dec;12(12):2760-71. doi: 10.1158/1535-7163.MCT-13-0487. Epub 2013 Oct 15.

3.

Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.

Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W, Presta M.

J Pathol. 2013 Jun;230(2):228-38. doi: 10.1002/path.4181.

PMID:
23424081
4.

Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation.

Maiolo D, Mitola S, Leali D, Oliviero G, Ravelli C, Bugatti A, Depero LE, Presta M, Bergese P.

J Am Chem Soc. 2012 Sep 5;134(35):14573-9. doi: 10.1021/ja305816p. Epub 2012 Aug 23.

PMID:
22860754
5.

Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.

Leali D, Inforzato A, Ronca R, Bianchi R, Belleri M, Coltrini D, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M.

Arterioscler Thromb Vasc Biol. 2012 Mar;32(3):696-703. doi: 10.1161/ATVBAHA.111.243998. Epub 2012 Jan 19.

6.

Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors.

Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S, Presta M.

Mol Cancer Ther. 2011 Sep;10(9):1600-10. doi: 10.1158/1535-7163.MCT-11-0286. Epub 2011 Jul 15.

7.

Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1.

Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M, Dell'Era P.

Mol Cancer Ther. 2010 Dec;9(12):3244-53. doi: 10.1158/1535-7163.MCT-10-0417. Epub 2010 Oct 12.

8.

Nanoliter contact angle probes tumor angiogenic ligand-receptor protein interactions.

Olivero G, Maiolo D, Leali D, Federici S, Depero LE, Presta M, Mitola S, Bergese P.

Biosens Bioelectron. 2010 Dec 15;26(4):1571-5. doi: 10.1016/j.bios.2010.07.115. Epub 2010 Aug 13.

PMID:
20810271
9.

Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2.

Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K, Zammataro L, Presta M.

Blood. 2010 Nov 4;116(18):3677-80. doi: 10.1182/blood-2010-06-291930. Epub 2010 Jul 21.

10.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

11.

Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides.

Leali D, Alessi P, Coltrini D, Rusnati M, Zetta L, Presta M.

Curr Pharm Des. 2009;15(30):3577-89. Review.

PMID:
19860702
12.

Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide.

Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L, Presta M.

J Cell Mol Med. 2010 Aug;14(8):2109-21. doi: 10.1111/j.1582-4934.2009.00855.x. Epub 2010 Jul 20.

13.

Inflammatory cells and chemokines sustain FGF2-induced angiogenesis.

Presta M, Andrés G, Leali D, Dell'Era P, Ronca R.

Eur Cytokine Netw. 2009 Jun;20(2):39-50. doi: 10.1684/ecn.2009.0155. Review.

14.

Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity.

Rusnati M, Bugatti A, Mitola S, Leali D, Bergese P, Depero LE, Presta M.

Sensors (Basel). 2009;9(8):6471-503. doi: 10.3390/s90806471. Epub 2009 Aug 20.

15.

A pro-inflammatory signature mediates FGF2-induced angiogenesis.

Andrés G, Leali D, Mitola S, Coltrini D, Camozzi M, Corsini M, Belleri M, Hirsch E, Schwendener RA, Christofori G, Alcamí A, Presta M.

J Cell Mol Med. 2009 Aug;13(8B):2083-108. doi: 10.1111/j.1582-4934.2008.00415.x.

16.

Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement.

Leali D, Moroni E, Bussolino F, Presta M.

J Biol Chem. 2007 Jul 6;282(27):19676-84. Epub 2007 Apr 23.

17.

Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes.

Naldini A, Leali D, Pucci A, Morena E, Carraro F, Nico B, Ribatti D, Presta M.

J Immunol. 2006 Oct 1;177(7):4267-70.

18.

Focal adhesion molecules as potential target of lead toxicity in NRK-52E cell line.

Giuliani R, Bettoni F, Leali D, Morandini F, Apostoli P, Grigolato P, Cesana BM, Aleo MF.

FEBS Lett. 2005 Nov 7;579(27):6251-8. Epub 2005 Oct 21.

19.

Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.

Presta M, Oreste P, Zoppetti G, Belleri M, Tanghetti E, Leali D, Urbinati C, Bugatti A, Ronca R, Nicoli S, Moroni E, Stabile H, Camozzi M, Hernandez GA, Mitola S, Dell'Era P, Rusnati M, Ribatti D.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):71-6. Epub 2004 Oct 28.

PMID:
15514208
20.

Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis.

Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A, Sozzani S, Nico B, Ribatti D, Presta M.

J Immunol. 2003 Jul 15;171(2):1085-93.

21.

Heparin derivatives as angiogenesis inhibitors.

Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, Moroni E, Liekens S, Rusnati M.

Curr Pharm Des. 2003;9(7):553-66. Review.

PMID:
12570803
22.

Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives.

Leali D, Belleri M, Urbinati C, Coltrini D, Oreste P, Zoppetti G, Ribatti D, Rusnati M, Presta M.

J Biol Chem. 2001 Oct 12;276(41):37900-8. Epub 2001 Jul 25.

23.

Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells.

Presta M, Rusnati M, Dell'Era P, Tanghetti E, Urbinati C, Giuliani R, Leali D.

Adv Exp Med Biol. 2000;476:7-34. Review.

PMID:
10949652
24.

In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2.

Ribatti D, Leali D, Vacca A, Giuliani R, Gualandris A, Roncali L, Nolli ML, Presta M.

J Cell Sci. 1999 Dec;112 ( Pt 23):4213-21.

25.

Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds.

Liekens S, Leali D, Neyts J, Esnouf R, Rusnati M, Dell'Era P, Maudgal PC, De Clercq E, Presta M.

Mol Pharmacol. 1999 Jul;56(1):204-13.

PMID:
10385702

Supplemental Content

Support Center